Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity

Oncogene

Volumn 34, Issue 24, 2015, Pages 3164-3175

  Riemer, P ^a,b   Sreekumar, A ^a,b   Reinke, S ^b   Rad, R ^c,d   Schafer R ^a,d   Sers, C ^a,d   Blaker H ^a   Herrmann, B G ^b   Morkel, M ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[4 (2,4 DICHLOROPHENYL) 5 (4 METHYL 1H IMIDAZOL 2 YL) 2 PYRIMIDINYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; B RAF KINASE; BETA CATENIN; BETA GALACTOSIDASE; DOXYCYCLINE; DUAL SPECIFICITY PHOSPHATASE 6; GLYCOGEN SYNTHASE KINASE 3BETA; JAGGED1; KRT20 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 2; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PHLDA1 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN; PROTEIN KINASE B; SELUMETINIB; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; WNT PROTEIN; WNT3A PROTEIN; BRAF PROTEIN, HUMAN; PROTO-ONCOGENE PROTEINS B-RAF;

ADULT; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BINDING SITE; CANCER CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FATE; CELL GRANULE; CELL LOSS; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; COLON CANCER; CONTROLLED STUDY; DIPLOIDY; DNA DAMAGE; DYSPLASIA; EMBRYO; EMBRYONIC STEM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GOBLET CELL; HISTOLOGY; HUMAN; HUMAN CELL; HYPERPLASIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTESTINAL STEM CELL; INTESTINE CRYPT; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PANETH CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSGENE; TRANSGENIC EXPRESSION; TUMOR GROWTH; WNT SIGNALING PATHWAY; ANIMALS; ANTAGONISTS AND INHIBITORS; CACO-2 CELLS; CARCINOGENESIS; CELL COUNT; COLONIC NEOPLASMS; GENETICS; HUMANS; INTESTINAL MUCOSA; INTESTINES; METABOLISM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PATHOLOGY; PHYSIOLOGY; STEM CELLS;

MUS;

ANIMALS; BETA CATENIN; CACO-2 CELLS; CARCINOGENESIS; CELL COUNT; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION; HUMANS; INTESTINAL MUCOSA; INTESTINES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS B-RAF; STEM CELLS; WNT SIGNALING PATHWAY;

EID: 84930823922     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.247     Document Type: Article

References (55)

1. Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nat Rev Mol Cell Biol 2013; 15: 19-33.
2. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-625.
3. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
4. Takahashi M, Nakatsugi S, Sugimura T, Wakabayashi K. Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000; 21: 1117-1120.
5. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256: 668-670.
6. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 2012; 13: 767-779.
7. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell2002; 111: 241-250.
8. van Es JH, Haegebarth A, Kujala P, Itzkovitz S, Koo B-K, Boj SF et al. A critical role for the Wnt effector Tcf4 in adult intestinal homeostatic self-renewal. Mol Cell Biol 2012; 32: 1918-1927.
9. Farrall AL, Riemer P, Leushacke M, Sreekumar A, Grimm C, Herrmann BG et al. Wnt and BMP signals control intestinal adenoma cell fates. Int J Cancer 2012; 131: 2242-2252.
10. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011; 42: 1-10.
11. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62: 367-386.
12. Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Järvinen H et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 2007; 26: 312-320.
13. Osaki LH, Gama P. MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci 2013; 14: 10143-10161.
14. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
15. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700.
16. Wu JM, Montgomery EA, Iacobuzio-Donahue CA. Frequent beta-catenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential. Am J Clin Pathol 2008; 129: 416-423.
17. Yachida S, Mudali S, Martin SA, Montgomery EA, Iacobuzio-Donahue CA. Betacatenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol 2009; 33: 1823-1832.
18. Rad R, Cadinanõs J, Rad L, Varela I, Strong A, Kriegl L et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013; 24: 15-29.
19. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS ONE 2011; 6: e25806.
20. Wan P, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
21. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868.
22. Vidigal JA, Morkel M, Wittler L, Brouwer-Lehmitz A, Grote P, Macura K et al. An inducible RNA interference system for the functional dissection of mouse embryogenesis. Nucleic Acids Res 2010; 38: e122.
23. Munõz J, Stange DE, Schepers AG, van de Wetering M, Koo B-K, Itzkovitz S et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent "+4" cell markers. EMBO J 2012; 31: 3079-3091.
24. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007.
25. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell2008; 132: 363-374.
26. Carragher LAS, Snell KR, Giblett SM, Aldridge VSS, Patel B, Cook SJ et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med 2010; 2: 458-471.
27. Gonzalo DH, Lai KK, Shadrach B, Goldblum JR, Bennett AE, Downs-Kelly E et al. Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol 2013; 230: 420-429.
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
29. Jürchott K, Kuban R-J, Krech T, Blüthgen N, Stein U, Walther W et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet 2010; 6: e1001231.
30. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S et al. Role of TAZ as mediator of Wnt signaling. Cell 2012; 151: 1443-1456.
31. Van der Flier L, Sabates Bellver J, Oving I. The intestinal Wnt/TCF signature. Gastroenterology 2007; 132: 628-632.
32. Merlos-Suárez A, Barriga FM, Jung P, Iglesias M, Céspedes MV, Rossell D et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-524.
33. Sato T, Stange DE, Ferrante M, Vries RGJ, van Es JH, van den Brink S et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011; 141: 1762-1772.
34. Farin HF, van Es JH, Clevers H. Redundant sources of wnt regulate intestinal stem cells and promote formation of paneth cells. Gastroenterology 2012; 143: e7.
35. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105: 3041-3046.
36. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogenactivated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007; 13: 1576-1583.
37. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3, 2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-5532.
38. Murray JT, Campbell DG, Morrice N, Auld GC, Shpiro N, Marquez R et al. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J 2004; 384: 477-488.
39. Ying Q-L, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J et al. The ground state of embryonic stem cell self-renewal. Nature 2008; 453: 519-523.
40. Kimura T, Yamamoto E, Yamano H-O, Suzuki H, Kamimae S, Nojima M et al. A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am J Gastroenterol 2012; 107: 460-469.
41. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011; 4: ra17.
42. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010; 3: ra84.
43. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
44. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol 2011; 7: 489.
45. Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A et al. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010; 18: 135-146.
46. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Göktuna SI, Ziegler PK et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stemcell-like properties. Cell 2012; 152: 25-38.
47. Vermeulen L, Morrissey E, van der Heijden M, Nicholson AM, Sottoriva A, Buczacki S et al. Defining stem cell dynamics in models of intestinal tumor initiation. Science 2013; 342: 995-998.
48. Moon B-S, Jeong W-J, Park J, Kim TI, Min DS, Choi K-Y. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/?-catenin signaling. J Natl Cancer Inst 2014; 106: djt373.
49. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K et al. A twostep model for colon adenoma initiation and progression caused by APC loss. Cell 2009; 137: 623-634.
50. Jeong W-J, Yoon J, Park J-C, Lee S-H, Lee S-H, Kaduwal S et al. Ras stabilization through aberrant activation of Wnt/?-catenin signaling promotes intestinal tumorigenesis. Sci Signal 2012; 5: ra30.
51. Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG et al. Wnt/?-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 2012; 5: ra3.
52. Guardavaccaro D, Clevers H. Wnt/?-catenin and MAPK signaling: allies and enemies in different battlefields. Sci Signal 2012; 5: pe15.
53. Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, van der Horst CMAM et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-724.
54. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009; 15: 294-303.
55. Herr R, Wöhrle FU, Danke C, Berens C, Brummer T. A novel MCF-10A line allowing conditional oncogene expression in 3D culture. Cell Commun Signal 2011; 9: 17.